TheraRadar
Data updated: May 26, 2026

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX (chlorpheniramine polistirex)

Respiratory Approved 2010-10-01

This combination medication helps adults manage coughs and upper respiratory symptoms caused by allergies or the common cold. It is used for patients 18 years of age and older when a healthcare provider determines that the benefits of suppressing a cough outweigh the potential risks associated with opioid use. Before use, clinicians should evaluate the underlying cause of the cough to ensure this treatment is appropriate

Source: FDA Label • TRIS PHARMA INC

How HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX Works

Hydrocodone is an opioid agonist with relative selectivity for the mu-opioid receptor; it is believed to suppress the cough reflex through a central mechanism of action in the cough center of the brain. Chlorpheniramine is an H1-receptor antagonist (antihistamine) that prevents released histamine from causing capillary dilation and edema of the respiratory mucosa. It also possesses anticholinergic and sedative activity.

Source: FDA Label
1
Indication
--
Phase 3 Trials
15
Years on Market

Details

Status
Prescription
First Approved
2010-10-01
Routes
ORAL
Dosage Forms
SUSPENSION, EXTENDED RELEASE

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX Approval History

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2010 to 2017
Dec 2017 SUPPL
Label · Labeling
Oct 2010 ORIGINAL
Update · Not Applicable

What HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX Treats

3 indications

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX is approved for 3 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Cough
  • Allergy
  • Common Cold
Source: FDA Label

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX Boxed Warning

ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION W...

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 16 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

3 of 12

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

PROMETHAZINE DM
DEXTROMETHORPHAN HYDROBROMIDE
3 shared
PAI HOLDINGS
Shared indications:
CoughAllergyCommon Cold
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE
2 shared
AMNEAL PHARMS
Shared indications:
AllergyCommon Cold
PROMETHAZINE W/ DEXTROMETHORPHAN
DEXTROMETHORPHAN HYDROBROMIDE
2 shared
PHARMOBEDIENT
Shared indications:
Common ColdCough
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX FDA Label Details

Indications & Usage

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX is indicated for the treatment of Cough; Allergy; Common Cold.

⚠️ BOXED WARNING

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, A...

Track HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.